Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Cash from Financing Activities (2010 - 2026)

Exelixis (EXEL) posted quarterly Cash from Financing Activities of -$457.1 million for Q2 2026, down 55.05% year-over-year from -$1.0 billion in Q2 2025, and down 79.56% quarter-over-quarter from -$254.6 million in Q1 2026.

Analysis

Exelixis (EXEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Exelixis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$457.1 million for Q2 2026.

  • In Q2 2026, Cash from Financing Activities fell 55.05% year-over-year to -$457.1 million; the TTM figure through Apr 2026 stood at -$1.1 billion (down 53.04% YoY), while the FY2026 annual figure was -$969.6 million, down 54.2% from the prior year.
  • Cash from Financing Activities for Q2 2026 stood at -$457.1 million, down from -$254.6 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $5.7 million in Q3 2024, with the low at -$457.1 million in Q2 2026.
  • The 5-year median for Cash from Financing Activities is -$184.0 million (2024), against an average of -$153.0 million.
  • Peak annual rise in Cash from Financing Activities reached 2137.07% in 2023, while the deepest fall reached 10678.85% in 2023.
  • Exelixis' Cash from Financing Activities stood at -$2.0 million in 2022, then slumped by 10193.21% to -$206.2 million in 2023, then jumped by 102.76% to $5.7 million in 2024, then sank by 1923.38% to -$103.9 million in 2025, then sank by 340.12% to -$457.1 million in 2026.
  • Business Quant data shows EXEL's Cash from Financing Activities at -$457.1 million in Q2 2026, -$254.6 million in Q1 2026, and -$103.9 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn -343.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 -343.88 Mn
Apr 3, 2026 -457.11 Mn
Jan 2, 2026 -254.57 Mn
Oct 3, 2025 -103.86 Mn
Jul 4, 2025 -316.34 Mn
Apr 4, 2025 -294.82 Mn
Jan 3, 2025 -188.03 Mn
Sep 27, 2024 5.70 Mn
Jun 28, 2024 -262.42 Mn
Mar 29, 2024 -184.05 Mn
Dec 29, 2023 -206.17 Mn
Sep 29, 2023 -219.67 Mn
Jun 30, 2023 -124.79 Mn
Mar 31, 2023 4.59 Mn
Dec 30, 2022 -2.00 Mn
Sep 30, 2022 -2.04 Mn
Jul 1, 2022 4.42 Mn
Apr 1, 2022 205,000.00
Dec 31, 2021 -17.99 Mn
Oct 1, 2021 -2.88 Mn